AQS.V - Aequus Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0900
0.0000 (0.00%)
At close: 3:39PM EDT
Stock chart is not supported by your current browser
Previous Close0.0900
Open0.0850
Bid0.0850 x 0
Ask0.0900 x 0
Day's Range0.0850 - 0.0900
52 Week Range0.0650 - 0.1900
Volume28,499
Avg. Volume64,681
Market Cap7.239M
Beta (5Y Monthly)0.24
PE Ratio (TTM)N/A
EPS (TTM)-0.0390
Earnings DateMay 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • GlobeNewswire

    Aequus Provides General Update and 2019 Financial Highlights

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the year ended December 31, 2019 (“Fiscal 2019”) and associated Company developments. “We had a strong end to 2019 and set new records for both quarterly and annual revenue,” said Doug Janzen, Chairman and CEO of Aequus. This past year, we were very pleased to add several new ophthalmology products to the commercial pipeline through our partnership with Medicom, and expect additional product announcements between Aequus and Medicom in the near term.

  • GlobeNewswire

    Aequus Announces Positive Update on Dry Eye Product Launch Plans

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce a positive update on the regulatory and launch advancement for the Evolve® line of preservative free dry eye products into Canada. The MDSAP, fully implemented by Health Canada in January 2019, establishes a new audit standard for all medical device manufacturers who distribute in Canada, including those with existing marketed products.

  • GlobeNewswire

    A Message from the CEO of Aequus Pharmaceuticals

    VANCOUVER, British Columbia, March 23, 2020 -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a.

  • GlobeNewswire

    Aequus Announces Appointment of New Director to its Board & Stock Option Grant

    In connection with Mr. Fowler's board appointment and his new role as strategic advisor to Aequus’ commercial team, the Company has granted him 350,000 incentive stock options. The Company has also granted 100,000 incentive stock options to an employee of the Company who is focused on the branding and launch preparation of the Evolve product line.

  • Does Aequus Pharmaceuticals Inc.'s (CVE:AQS) CEO Pay Compare Well With Peers?
    Simply Wall St.

    Does Aequus Pharmaceuticals Inc.'s (CVE:AQS) CEO Pay Compare Well With Peers?

    Doug Janzen has been the CEO of Aequus Pharmaceuticals Inc. (CVE:AQS) since 2014. This report will, first, examine the...

  • GlobeNewswire

    Aequus and Medicom Announce Changes to their Respective Commercial Leadership Teams

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that Ian Ball, Chief Commercial Officer, will transition to a full-time senior management role with the Company’s partner, Medicom Healthcare in the UK, as of February 1st, 2020. As part of the transition, Aequus is pleased to welcome Stu Fowler to the team, one of the most experienced commercial ophthalmology executives in Canada.

  • GlobeNewswire

    Aequus Receives Positive Formulary Decision in British Columbia for Specialty Portfolio Product

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that a major health authority in British Columbia recently announced a change to their dispensing formulary for tacrolimus, an immunosuppressive drug that is used to prevent organ rejection after transplantation. As of November 4, 2019, the health authority mandated that Sandoz tacrolimus, co-promoted by Aequus, is to be dispensed for all new patients requiring tacrolimus for prophylaxis of organ rejection in the province of British Columbia.

  • GlobeNewswire

    Aequus to Broaden Vistitan Reimbursement for Patients in Canada

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it has advanced the filings for provincial reimbursement in both Quebec and British Columbia for its lead product, PrVistitanTM (bimatoprost 0.03%). If successful, this additional coverage would advance sales in the second and third largest markets in Canada and would trigger an increase in the percentage of total revenue that Aequus receives from its partner.

  • GlobeNewswire

    Aequus and Medicom Healthcare Sign Exclusive Term Sheet To Jointly Advance Ophthalmology Products Into The USA

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce the signing of a term sheet to co-commercialize a portfolio of products in the USA with Medicom Healthcare, a United Kingdom based pharmaceutical company with a focus on preservative free therapies in ophthalmology. Under the proposed agreement, Aequus and Medicom will jointly commercialize Medicom’s range of preservative free ophthalmics in the United States of America.

  • GlobeNewswire

    Aequus Provides Third Quarter 2019 Financial Highlights

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended September 30, 2019 (“Q3 2019”) and associated Company developments. “Aequus has continued to advance the business in Q3, signing a key collaboration with Medicom Healthcare which adds a collection of market-ready ophthalmology products along with late-stage development assets to our growing ophthalmology franchise in Canada,” said Doug Janzen, Charmain and CEO of Aequus.

  • Imagine Owning Aequus Pharmaceuticals (CVE:AQS) While The Price Tanked 56%
    Simply Wall St.

    Imagine Owning Aequus Pharmaceuticals (CVE:AQS) While The Price Tanked 56%

    Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...

  • GlobeNewswire

    Aequus Highlights Study Indicating Vistitan as the Most Effective Treatment for Glaucoma

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) today acknowledged the research results presented at the American Academy of Ophthalmology in San Francisco that revealed bimatoprost 0.03%, branded as PrVistitanTM  and promoted by Aequus in Canada, as the most efficacious topical treatment currently available for glaucoma and ocular hypertension in terms of intraocular pressure. The study, conducted by Dr. Paul Harasymowycz and his team, assessed the comparative efficacy of latanoprostene bunod to other treatments for intraocular pressure reduction at three months.

  • GlobeNewswire

    Aequus Replaces Expired Short Form Base Shelf Prospectus

    Aequus Pharmaceuticals Inc. (TSX-V : AQS, OTCQB : AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that, further to its press release dated August 27, 2019, it has received a receipt for its final short form base shelf prospectus (the “Prospectus”). The Prospectus will allow Aequus to offer, subject to the filing of a shelf prospectus supplement, up to C$20,000,000 of common shares, preferred shares, debt securities, subscription receipts, units and warrants from time to time, in each of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, until the Prospectus expires on October 16, 2021.

  • Should You Worry About Aequus Pharmaceuticals Inc.'s (CVE:AQS) CEO Pay?
    Simply Wall St.

    Should You Worry About Aequus Pharmaceuticals Inc.'s (CVE:AQS) CEO Pay?

    Doug Janzen has been the CEO of Aequus Pharmaceuticals Inc. (CVE:AQS) since 2014. First, this article will compare CEO...

  • GlobeNewswire

    A Return to Revenue Growth - Aequus Provides Second Quarter 2019 Financial Highlights

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the six months ended June 30, 2019 (“Q2 2019”) and associated Company developments. “We’re pleased to announce a return to revenue growth in the second quarter,” said Doug Janzen, Charmain and CEO of Aequus.

  • GlobeNewswire

    Aequus Signs Exclusive Distribution Agreement with Medicom Healthcare for Canadian Distribution Rights of Ophthalmic Products

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of an exclusive distribution agreement with Medicom Healthcare Ltd. (“Medicom”), a United Kingdom based pharmaceutical company with a focus on preservative free therapies in ophthalmology. Under the distribution agreement, Aequus will receive commercial rights to novel portions of Medicom’s portfolio of ophthalmology products including the Evolve® line of preservative free dry eye products within Canada.

  • Do Directors Own Aequus Pharmaceuticals Inc. (CVE:AQS) Shares?
    Simply Wall St.

    Do Directors Own Aequus Pharmaceuticals Inc. (CVE:AQS) Shares?

    If you want to know who really controls Aequus Pharmaceuticals Inc. (CVE:AQS), then you'll have to look at the makeup...

  • GlobeNewswire

    Aequus Provides First Quarter 2019 Financial Highlights

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended March 31, 2019 (“Q1 2019”) and associated Company developments. “Aequus continues to drive its promotional efforts forward with Q1 2019 unit growth of 27% and 5.3% over Q1 2018 in our main revenue drivers, Vistitan and Tacrolimus, respectively,” said Doug Janzen, Chairman and CEO of Aequus. The decrease is attributable to a contractual step down in profit share for both Tacrolimus and PRVistitan™ (“Vistitan”).

  • GlobeNewswire

    Aequus to Clarify Press Release of 23rd May 2019 Relating to Zepto Capsulotomy System and Kensington Eye Institute

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) confirms its release of 23rd May 2019. Aequus is pleased to be a supplier of the Zepto Capsulotomy System (“the Product”) with the Kensington Eye Institute in Ontario, Canada.